Savant Capital LLC Purchases 34,082 Shares of Accolade, Inc. (NASDAQ:ACCD)

Savant Capital LLC lifted its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 182.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,794 shares of the company’s stock after purchasing an additional 34,082 shares during the quarter. Savant Capital LLC owned 0.06% of Accolade worth $181,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ACCD. Mission Creek Capital Partners Inc. bought a new position in shares of Accolade during the third quarter worth $38,000. Pallas Capital Advisors LLC bought a new position in shares of Accolade during the fourth quarter worth $38,000. Wolverine Trading LLC acquired a new stake in shares of Accolade during the third quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Accolade by 1,144.1% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock worth $81,000 after acquiring an additional 19,232 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of Accolade during the third quarter worth $96,000. 84.99% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Canaccord Genuity Group restated a “hold” rating on shares of Accolade in a report on Wednesday, January 8th. Leerink Partners restated a “market perform” rating on shares of Accolade in a report on Wednesday, January 8th. William Blair lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 8th. Morgan Stanley dropped their price objective on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Finally, Raymond James restated a “market perform” rating on shares of Accolade in a report on Thursday, January 9th. Twelve investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Accolade has an average rating of “Hold” and an average price target of $7.46.

Accolade Stock Down 0.3 %

Shares of ACCD stock opened at $6.89 on Thursday. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. Accolade, Inc. has a 1 year low of $3.08 and a 1 year high of $12.24. The firm’s fifty day moving average price is $5.51 and its two-hundred day moving average price is $4.40. The firm has a market capitalization of $562.16 million, a P/E ratio of -3.06 and a beta of 2.20.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities analysts predict that Accolade, Inc. will post -1.2 EPS for the current fiscal year.

Insider Transactions at Accolade

In other news, CEO Rajeev Singh sold 13,357 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total transaction of $48,085.20. Following the transaction, the chief executive officer now directly owns 814,316 shares in the company, valued at $2,931,537.60. The trade was a 1.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 40,472 shares of company stock worth $162,479 in the last ninety days. Insiders own 8.20% of the company’s stock.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.